The present invention discloses the crystal type of B, which is characterized in that the use of Cu-K radiation, X- ray powder diffraction to angle 2 representation (X-RPD) in the 6.4 - 0.2 degrees, 7.9 degrees and 8.7 + 0.2, 9.8 + 0.2 + 0.2 degrees, 10 degrees, plus or minus 0.2 degrees, there are 17 + 0.2 degrees at the peak. The crystalline B of the invention can be prepared and purified on a large scale, and the storage is stable, and the utility model is not suitable for the preparation of the inhalation preparation, and is compatible with the lactose, starch and other excipients.
【技术实现步骤摘要】
本专利技术涉及药物化学领域,具体地,本专利技术涉及N-[3-叔-丁基-1-(3-氯-4-羟基苯基)-1H-吡唑-5-基]-N′-{2-[(3-{2-[(2-羟乙基)硫基]苯基
【技术保护点】
晶型B,其特征在于,使用Cu‑Kα辐射,以2θ角度表示的X‑ 射线粉末衍射(X‑RPD) 在6.4±0.2°,7.9±0.2°,8.7±0.2 °,9.8±0.2 °,10.0±0.2 °,17.0±0.2°处有衍射峰。
【技术特征摘要】
1.晶型B,其特征在于,使用Cu-Kα辐射,以2θ角度表示的X-射线粉末衍射(X-RPD)在6.4±0.2°,7.9±0.2°,8.7±0.2°,9.8±0.2°,10.0±0.2°,17.0±0.2°处有衍射峰。
2.根据权利要求1所述的依鲁替尼的晶型B,其特征在于,使用Cu-Kα辐射,以2θ角度表示的X-射线粉末衍射在4.0±0.2°,6.0±0.2°,6.4±0.2°,7.9±0.2°,8.7±0.2°,9.8±0.2°,10.0±0.2°,12.3±0....
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。